⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8885478 | 0.82 | GPR84 (0.72) | — | |
| SCHEMBL8883686 | 0.79 | GPR84 (0.86) | — | |
| SCHEMBL8203881 | 0.77 | GPR84 (0.96) | — | |
| SCHEMBL6930696 | 0.76 | — | — | |
| SCHEMBL38665365 | 0.76 | — | — | |
| SCHEMBL1161426 | 0.76 | — | — | |
| SCHEMBL10568048 | 0.76 | — | — | |
| SCHEMBL14076736 | 0.76 | GPR84 (0.50) | — | |
| SCHEMBL26986362 | 0.76 | GPR84 (0.50) | — | |
| SCHEMBL17761925 | 0.76 | GPR84 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292559-B | Morphinan derivatives | 日本化学药品株式会社 | 2024-04-02 | — | — | CN | disclosed |
| CN-117122598-A | Use of morphinan derivatives in the treatment of opioid delta receptor agonist-related diseases | 日本化学药品株式会社 | 2023-11-28 | — | — | CN | disclosed |
| CN-116997360-A | Pharmaceutical composition for treating or preventing stress-related disorders | 学校法人东京理科大学 | 2023-11-03 | — | — | CN | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| CN-110248658-B | Use of morphinan derivatives in the treatment of opioid delta receptor agonist-related diseases | 日本化学药品株式会社 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023183437-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023086799-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022133480-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | CYCLERION THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11319308-B2 | Processes for preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20090111822-A1 | 1,2,3-TRIAZOLE PYRROLIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-22 | — | — | US | disclosed |
| US-20080045480-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080004282-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | PITLIK JANOS | 2007-12-20 | — | — | US | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-12 | — | — | US | disclosed |
| US-7241796-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-19 | — | — | US | disclosed |
| US-4451469-A | Selected 6-alkyl-and 4,6-dialkyl-2(1H)-pyridinones as cardiotonics | STERLING DRUG INC. (US) | 1984-05-29 | — | — | US | disclosed |